Pfizer buys seat at biosimilars table next to Biocon

Biocon will continue to handle the development, manufacture and supply of biosimilar versions of its insulin and insulin analog products, following a deal with Pfizer. Analogs include Recombinant Human Insulin, Glargine, Aspart and Lispro. For its part, Pfizer will commercialize the products globally. Biocon announcement

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.